- Home
- Publications
- Publication Search
- Publication Details
Title
New developments in castrate-resistant prostate cancer
Authors
Keywords
-
Journal
BJU INTERNATIONAL
Volume 109, Issue -, Pages 22-32
Publisher
Wiley
Online
2012-06-05
DOI
10.1111/j.1464-410x.2012.11217.x
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Cabazitaxel or mitoxantrone with prednisone in patients with metastatic castration-resistant prostate cancer (mCRPC) previously treated with docetaxel: Final results of a multinational phase III trial (TROPIC).
- (2017) J. S. De Bono et al. JOURNAL OF CLINICAL ONCOLOGY
- Phase II study of XL184 in a cohort of patients (pts) with castration-resistant prostate cancer (CRPC) and measurable soft tissue disease.
- (2017) D. C. Smith et al. JOURNAL OF CLINICAL ONCOLOGY
- An evaluation of clusterin antisense inhibitor OGX-011 in combination with the second-generation antiandrogen MDV3100 in a castrate-resistant prostate cancer model.
- (2017) H. Matsumoto et al. JOURNAL OF CLINICAL ONCOLOGY
- Effect of MDV3100, an androgen receptor signaling inhibitor (ARSI), on overall survival in patients with prostate cancer postdocetaxel: Results from the phase III AFFIRM study.
- (2017) Howard I. Scher et al. JOURNAL OF CLINICAL ONCOLOGY
- Phase II Trial of Weekly Ixabepilone in Men With Metastatic Castrate-Resistant Prostate Cancer (E3803): A Trial of the Eastern Cooperative Oncology Group
- (2012) Glenn Liu et al. Clinical Genitourinary Cancer
- A review of the history, properties, and use of the immunomodulatory compound lenalidomide
- (2011) Jerome B. Zeldis et al. Annals of the New York Academy of Sciences
- Discovery of orteronel (TAK-700), a naphthylmethylimidazole derivative, as a highly selective 17,20-lyase inhibitor with potential utility in the treatment of prostate cancer
- (2011) Tomohiro Kaku et al. BIOORGANIC & MEDICINAL CHEMISTRY
- Upregulation of MAPK pathway is associated with survival in castrate-resistant prostate cancer
- (2011) R Mukherjee et al. BRITISH JOURNAL OF CANCER
- Phase I study of BIBF 1120 with docetaxel and prednisone in metastatic chemo-naive hormone-refractory prostate cancer patients
- (2011) G Bousquet et al. BRITISH JOURNAL OF CANCER
- Dasatinib combined with docetaxel for castration-resistant prostate cancer
- (2011) John C. Araujo et al. CANCER
- Targeting Continued Androgen Receptor Signaling in Prostate Cancer
- (2011) C. Massard et al. CLINICAL CANCER RESEARCH
- Randomized Phase II Trial of Custirsen (OGX-011) in Combination with Docetaxel or Mitoxantrone as Second-line Therapy in Patients with Metastatic Castrate-Resistant Prostate Cancer Progressing after First-line Docetaxel: CUOG Trial P-06c
- (2011) F. Saad et al. CLINICAL CANCER RESEARCH
- Overall Survival Benefit of Radium-223 Chloride (Alpharadin™) in the Treatment of Patients with Symptomatic Bone Metastases in Castration-resistant Prostate Cancer (CRPC): a Phase III Randomized Trial (ALSYMPCA)
- (2011) C. Parker et al. EUROPEAN JOURNAL OF CANCER
- Circulating Tumour Cells as Surrogate Biomarkers in Castration-Resistant Prostate Cancer Trials
- (2011) Anders Bjartell EUROPEAN UROLOGY
- Novel Prognostic Markers in the Serum of Patients With Castration-Resistant Prostate Cancer Derived From Quantitative Analysis of the Pten Conditional Knockout Mouse Proteome
- (2011) Martin Kälin et al. EUROPEAN UROLOGY
- Inecalcitol, an analog of 1α,25(OH)2D3, induces growth arrest of androgen-dependent prostate cancer cells
- (2011) Ryoko Okamoto et al. INTERNATIONAL JOURNAL OF CANCER
- A phase II study of sorafenib in combination with bicalutamide in patients with chemotherapy-naive castration resistant prostate cancer
- (2011) Emma K. Beardsley et al. INVESTIGATIONAL NEW DRUGS
- Anti-CTLA4 monoclonal antibodies: the past and the future in clinical application
- (2011) Paolo A Ascierto et al. Journal of Translational Medicine
- Clinical outcomes of active specific immunotherapy in advanced colorectal cancer and suspected minimal residual colorectal cancer: a meta-analysis and system review
- (2011) Benqiang Rao et al. Journal of Translational Medicine
- 710 DOSE FINDING AND EFFICACY PHASE 2 STUDY OF INECALCITOL, A NEW VDR AGONIST, IN COMBINATION WITH DOCETAXEL-PREDNISONE REGIMEN FOR CASTRATION-RESISTANT PROSTATE CANCER (CRPC) PATIENTS (PTS)
- (2011) Jacques Medioni et al. JOURNAL OF UROLOGY
- 1275 PHASE I CLINICAL TRIAL OF NOVEL CDCA1 DERIVED EPITOPE PEPTIDE VACCINE THERAPY FOR CASTRATION-RESISTANT PROSTATE CANCER
- (2011) Wataru Obara et al. JOURNAL OF UROLOGY
- 1453 REGULATION OF INTRACRINE ANDROGEN SYNTHESIS BY NF-KAPPAB2/P52
- (2011) Nagalakshmi Nadiminty et al. JOURNAL OF UROLOGY
- 138 EXPRESSION OF GENES ENCODING ENZYMES INVOLVED IN ANDROGEN SYNTHESIS IN HUMAN ADIPOSE TISSUE - POSSIBILITY OF ADIPOSE TISSUE AS THE THIRD ORGAN PRODUCING ACTIVE ANDROGEN IN PROSTATE CANCER PATIENTS-
- (2011) Seiji Arai et al. JOURNAL OF UROLOGY
- Abiraterone and Increased Survival in Metastatic Prostate Cancer
- (2011) Johann S. de Bono et al. NEW ENGLAND JOURNAL OF MEDICINE
- The Epothilones: New Therapeutic Agents for Castration-Resistant Prostate Cancer
- (2011) T. B. Dorff et al. ONCOLOGIST
- A phase 2 study of estramustine, docetaxel, and bevacizumab in men with castrate-resistant prostate cancer
- (2010) Joel Picus et al. CANCER
- Elevated plasma tissue inhibitor of metalloproteinase-1 levels predict decreased survival in castration-resistant prostate cancer patients
- (2010) William K. Oh et al. CANCER
- Ixabepilone, mitoxantrone, and prednisone for metastatic castration-resistant prostate cancer after docetaxel-based therapy
- (2010) Andrea L. Harzstark et al. CANCER
- A modular Phase I study of lenalidomide and paclitaxel in metastatic castration-resistant prostate cancer following prior taxane therapy
- (2010) P. Mathew et al. CANCER CHEMOTHERAPY AND PHARMACOLOGY
- Targeting the Cytoprotective Chaperone, Clusterin, for Treatment of Advanced Cancer
- (2010) A. Zoubeidi et al. CLINICAL CANCER RESEARCH
- Therapeutic Cancer Vaccines in Combination with Conventional Therapy
- (2010) Mads Hald Andersen et al. JOURNAL OF BIOMEDICINE AND BIOTECHNOLOGY
- Overall Survival Analysis of a Phase II Randomized Controlled Trial of a Poxviral-Based PSA-Targeted Immunotherapy in Metastatic Castration-Resistant Prostate Cancer
- (2010) Philip W. Kantoff et al. JOURNAL OF CLINICAL ONCOLOGY
- New Therapies for Castration-Resistant Prostate Cancer
- (2010) Dan L. Longo NEW ENGLAND JOURNAL OF MEDICINE
- Sipuleucel-T Immunotherapy for Castration-Resistant Prostate Cancer
- (2010) Philip W. Kantoff et al. NEW ENGLAND JOURNAL OF MEDICINE
- Ipilimumab: Unleashing the Power of the Immune System Through CTLA-4 Blockade
- (2010) Peter Boasberg et al. SEMINARS IN ONCOLOGY
- SPECIFIC ENDOTHELIN-A RECEPTOR ANTAGONISM FOR THE TREATMENT OF ADVANCED PROSTATE CANCER
- (2009) Karim Fizazi et al. BJU INTERNATIONAL
- Circulating Tumor Cells in Patients with Castration-Resistant Prostate Cancer Baseline Values and Correlation with Prognostic Factors
- (2009) O. B. Goodman et al. CANCER EPIDEMIOLOGY BIOMARKERS & PREVENTION
- Phase II Study of Dasatinib in Patients with Metastatic Castration-Resistant Prostate Cancer
- (2009) E. Y. Yu et al. CLINICAL CANCER RESEARCH
- Phase II Study of Androgen Synthesis Inhibition with Ketoconazole, Hydrocortisone, and Dutasteride in Asymptomatic Castration-Resistant Prostate Cancer
- (2009) M.-E. Taplin et al. CLINICAL CANCER RESEARCH
- Circulating Prostate Tumor Cells Detected by Reverse Transcription-PCR in Men with Localized or Castration-Refractory Prostate Cancer: Concordance with CellSearch Assay and Association with Bone Metastases and with Survival
- (2009) P. Helo et al. CLINICAL CHEMISTRY
- The development of risk groups in men with metastatic castration-resistant prostate cancer based on risk factors for PSA decline and survival
- (2009) Andrew J. Armstrong et al. EUROPEAN JOURNAL OF CANCER
- Tumor immunosuppressive environment: effects on tumor-specific and nontumor antigen immune responses
- (2009) Ana Paula de Souza et al. Expert Review of Anticancer Therapy
- Selective Inhibition of CYP17 With Abiraterone Acetate Is Highly Active in the Treatment of Castration-Resistant Prostate Cancer
- (2009) Gerhardt Attard et al. JOURNAL OF CLINICAL ONCOLOGY
- Genomic Strategy for Targeting Therapy in Castration-Resistant Prostate Cancer
- (2009) Prateek Mendiratta et al. JOURNAL OF CLINICAL ONCOLOGY
- Inhibition of prostate cancer cell growth by second-site androgen receptor antagonists
- (2009) J. D. Joseph et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- Phase 3, randomized, controlled trial of atrasentan in patients with nonmetastatic, hormone-refractory prostate cancer
- (2008) Joel B. Nelson et al. CANCER
- Androgen Levels Increase by Intratumoral De novo Steroidogenesis during Progression of Castration-Resistant Prostate Cancer
- (2008) J. A. Locke et al. CANCER RESEARCH
- Maintenance of Intratumoral Androgens in Metastatic Prostate Cancer: A Mechanism for Castration-Resistant Tumor Growth
- (2008) R. B. Montgomery et al. CANCER RESEARCH
- Evidence-Based Standards for Cancer Pain Management
- (2008) Sydney M. Dy et al. JOURNAL OF CLINICAL ONCOLOGY
- Design and End Points of Clinical Trials for Patients With Progressive Prostate Cancer and Castrate Levels of Testosterone: Recommendations of the Prostate Cancer Clinical Trials Working Group
- (2008) Howard I. Scher et al. JOURNAL OF CLINICAL ONCOLOGY
- Alternative Nonsteroidal Antiandrogen Therapy for Advanced Prostate Cancer That Relapsed After Initial Maximum Androgen Blockade
- (2008) Hiroyoshi Suzuki et al. JOURNAL OF UROLOGY
Publish scientific posters with Peeref
Peeref publishes scientific posters from all research disciplines. Our Diamond Open Access policy means free access to content and no publication fees for authors.
Learn MoreBecome a Peeref-certified reviewer
The Peeref Institute provides free reviewer training that teaches the core competencies of the academic peer review process.
Get Started